Clinical Research Fellowship: Awardees & Reports

2018 Fellowship 

Cardiotoxicity Related to Systemic Anti-HER2 Therapies: sub-analysis of ALTTO and APHINITY trials
eiger-daniel

Fellow: Daniel Eiger
Home institute: Centro Paulista de Oncologia, Sao Paolo, Brazil
Host institute: Institute Jules Bordet, Brussels, Belgium
Sponsor: Novartis

2017 Fellowship

Health Behaviors and Long-term Treatment Toxicity Among Breast Cancer Survivors: A Quantitative Analysis in the French Prospective CANTO Cohort

di-meglio-antonio

Fellow: Antonio Di Meglio 
Home Institute: IRCCS AOU San Martino, Genoa, Italy
Host institute: Institut Gustave Roussy, Villejuif, France
Sponsor: ESMO

A Phase I-II Investigation of Pembrolizumab in Combination with Oral Metronomic Cyclophosphamide in Patients with Locally Recurrent, Inoperable, and/or Metastatic Inflammatory Breast Cancer with Lymphangitic Spread to the Chest Wall

duso-bruno

Fellow: Bruno Duso 
Home Institute: Hospital Moinhos de Vento, Porto Alegre, Brazil
Host institute: Istituto Europeo di Oncologia, Milan, Italy
Sponsor: ESMO

Download the report

LAsting Symptoms after Esophageal Resection (LASER)

markar-sheraz

Fellow: Sheraz Markar 
Home Institute: St. Mary's Hospital Imperial College, London, United Kingdom
Host institute: Karolinska Instituttet, Stockholm, Sweden
Sponsor: Novartis

2016 Fellowship

Inflammation markers and prognostic model of survival and toxicity in patients with advanced pancreatic cancer (APC) receiving palliative Gemcitabine-based chemotherapy: insights from the SAKK 44/00-CECOG/PAN.1.3.001

gargiulo-piera

Fellow: Piera Gargiulo
Home institute: Istituto Nazionale Tumori- I.R.C.C.S - Fondazione Pascale, Napoli, Italy
Host institute: Swiss Group for Clinical Cancer Research SAKK, Bern, Switzerland
Sponsor: Novartis

Download the report

Read the publication

2015 Fellowship

Study of prognostic factors in patients with BRAF-mutant metastatic melanoma treated with targeted therapies

valpione-sara

Fellow: Sara Valpione
Home Institute: University of Padova, Italy
Host Institute: The Christie NHS Foundation Trust, University of Manchester, United Kingdom
Sponsor: Novartis 

2014 Fellowship

Co-targeting of AKT and the Androgen Receptor for Advanced Prostate Cancer

Michael Kolinsky

Fellow: Michael Kolinsky
Home Institute: University of Alberta Cross Cancer Institute, Edmonton, Alberta, Canada
Host Institute: The Institute of Cancer Research and Royal Marsden NHS Foundation Trust, Sutton, Surrey, UK
Sponsor: Novartis  

2013 Fellowships

Molecular resistance following personalised therapy in colorectal cancer (FOCUS-4 clinical fellow)

Tal Grenader

Fellow: Tal Grenader
Home Institute: Shaare Zedek Medical Centre, Jerusalem, Israel
Host Institute: UCL, Cancer Institute, University College London, United Kingdom
Sponsor: Novartis  

Metabolomic study in renal cell carcinoma (RCC): patterns of relapsed and follow up

Guillermo Antonio De Velasco Oria

Fellow: Guillermo Antonio De Velasco Oria
Home Institute: University Hospital 12 De Octubre, Medical Oncology, Madrid, Spain
Host Institute: Addenbrookes Hospital, Cambridge University Hospitals NHS Foundation Trust, Cambridge, United Kingdom
Sponsor: Novartis

2011 Fellowship

Association between insulin resistance and pathologic response to neoadjuvant chemotherapy among women with operable hormone receptor negative breast cancer

 Alejandra Alonso

Fellow: Alejandra Armengol Alonso
Home Institute: Instituto Nacional De Ciencias Medicias y Nutricion, Mexico City, Mexico
Host Institute: Barcelona Hospital Universitari, Barcelona, Spain
Sponsor: Novartis

Download the report

2010 Fellowships

Treatment of naïve and fludarabine-refractory CLL in the TCL-1 mouse model with IPI-926 and other hedgehog pathway inhibitors

Fellow: Michael Baumann
Home Institute: Department of Medical Oncology, Kantonsspital, St. Gallen, Switzerland
Host Institute:Laboratory of Molecular Biology and Immunology CLL, Dept of Haematology and Oncology, University of Cologne, Germany
Sponsor: ESMO

Download the report

Prostate Cancer Genetics and targeted screening

Fellow: Elena Castro Marcos
Home Institute: Centro de Investigacion del Cancer, Hospital Universitario de Salamanca, Spain
Host Institute: Royal Marsden Hospital NHS Trust, and The institute of Cancer Research, London, United Kingdom
Sponsor: Novartis

Download the report

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings